PATIENTS WITH REFRACTORY ANGINA ARE OFTEN CALLED NO OPTION PATIENTS

The Neovasc Reducer™ System Puts a Solution in Your Hands

innovative cardiovascular devices

neovasc

THE PROBLEM OF REFRACTORY ANGINA

Refractory angina is caused by coronary insufficiency due to obstructive coronary artery disease. It is a type of reversible myocardial ischemia that cannot be controlled by a combination of medical therapy, angioplasty or coronary bypass surgery[1]. Consequently patients are typically labelled "no option" patients[2].

Refractory angina leads to
- Significant disability
- Limited quality of life
- Multiple medications
- Frequent hospital admissions [1, 3, 4, 5, 6, 7]

It has been estimated that between **2 and 4%** of the population have angina[8].

Up to **10%** of these patients have refractory angina[9], the prevalence of which continues to increase[1].

[1] European Heart Journal 2002:23,355-370
[2] Nature Review Cardiology 2014;11:78-95
[3] European Heart Journal 2013 34, 2949–3003
[4] European Heart Journal 2006;27:1007-1009
[5] Heart 2004;90:225-230
[6] Am J Cardiol1999;84:598–600
[7] Can J Cardiol 2009;25(7):399-401
[8] ESC 2006
[9] ESC Joint Study Group 2002



The Neovasc Reducer™ System: A novel solution

The Reducer is a balloon expandable hourglass-shaped metal mesh. When implanted in the coronary sinus (CS) it creates a focal narrowing to modulate flow and elevate CS pressure. CS narrowing has been demonstrated to improve perfusion to ischemic territories of the myocardium[10] and can lead to relief of symptoms in patients with refractory angina.

The Reducer is intended to increase sub-endocardial perfusion

The Reducer is typically introduced into the coronary sinus by right heart catheterization through the right internal jugular vein, where it creates a slight increase in pressure and improves sub-endocardial perfusion.



HEALTHY MYOCARDIUM
ENDO/EPI BLOOD FLOW RATIO = 1.2

ISCHEMIC MYOCARDIUM
ENDO/EPI BLOOD FLOW RATIO = 0.5

ISCHEMIC MYOCARDIUM WITH CORONARY SINUS OCCLUSION
ENDO/EPI BLOOD FLOW RATIO = 1.2

[10] Am J Physiol Heart Circ Physiolo 280:H13610-H1367, 2001

"Reducer implantation was significantly better than a sham intervention to improve angina symptoms in patients with advanced coronary artery disease unsuitable for revascularization and treated with optimal therapy"[11]

Cardiac death	0	1
MI	2*	3

* Two events occurred in the same patient. One peri-procedural NSTEMI adjudicated as possibly related to the timing of the procedure. The second NSTEMI was adjudicated as not related to the procedure or device, but a progression of disease in the LCx artery.

FIM Long-term safety after 3 years[12]

	Baseline	6 months	3 years	P value
CCS class	3.07 ± 0.11	1.73 ± 0.22	1.57 ± 0.23	0.006
Dobutamine Echo ischemia severity	1.33 ± 0.28	0.55 ± 0.25	0.45 ± 0.16	0.02
Thallium SPECT ischemia severity	1.93 ± 0.06	1.47 ± 0.13	0.82 ± 0.26	0.03
Maximal ST segment depression	1.67 ± 0.33	0.78 ± 0.22	0.67 ± 0.33	0.03

The safety and performance of the Neovasc Reducer™ System is maintained 3 years after implantation. The improvement in angina and ischemia severity observed 6 months after implantation of the Reducer was maintained for 3 years[12].

As with any medical procedure there are risks associated with use of the Neovasc Reducer™ System including, but not limited to, myocardial infarction, continued angina, and implant migration/dislodgement requiring medical intervention. For a complete list of potential complications consult the device Instructions for Use.

[11] New England Journal of Medicine, 2015;372:517-25
[12] JACC March 9 2010 Volume 55 Issue 10A A98.E927

neovasc

Neovasc Inc., headquartered in Vancouver, B.C. Canada, is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ System for the treatment of refractory angina, Tiara™ Mitral Valve with the Tiara™ Delivery System (in development) for the transcatheter treatment of mitral valve disease, and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as transcatheter heart valves.

Code	Product
RED-001	The Neovasc Reducer™ System

For all orders, prices,deliveries and general enquiries:

Aquilant Interventional

Aquilant Interventional

Monday to Friday
8.00am – 5.30pm

T: +44 (0) 845 6024 007
F: +44 (0) 1256 365486

E: contactus@aquilantinterventional.com
W: www.aquilantinterventional.com